249 patents currently held
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
38
Ending by 2030
Dec 2026
Next term end
120
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2028 · High confidence
Also notable
Ends Jul 2036 · High confidence
Also notable
Ends no later than Nov 2027 · Medium confidence
Antibodies to IL-6 and Use Thereof
US 7,935,340
The most cited patent in this portfolio, cited by 148 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
Agents, Uses and Methods for the Treatment of Synucleinopathy
US 11,542,323
Cited by 12 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Methods of Synthesizing Heteromultimeric Polypeptides in Yeast Using a Haploid Mating Strategy
US 7,927,863
Cited by 89 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Pyrazole Compounds and Methods of Making and Using Same (US 10,323,038) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 11 fees due Jan 2 to 30, 2027 · next Jan 2
- 5 fees due Feb 13 to 28, 2027 · next Feb 13
- 2 fees due Mar 15, 2027
- 2 fees due Apr 1 to 10, 2027 · next Apr 1
- 7 fees due May 5 to 28, 2027 · next May 5
- 8 fees due Jun 10 to 30, 2027 · next Jun 10
- 6 fees due Jul 2 to 28, 2027 · next Jul 2
- 3 fees due Aug 4 to 18, 2027 · next Aug 4
- 3 fees due Sep 8 to 26, 2027 · next Sep 8
- 6 fees due Oct 12 to 28, 2027 · next Oct 12
- 4 fees due Nov 5 to 12, 2027 · next Nov 5
Recent changes
- Oct 13Assignment recorded on 1 record: Juhl, Karsten and 10 others to H. Lundbeck A/S Recorded Oct 13, 2026, executed Mar 20, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76355, frame 76.
- 2 of the patents on this record were granted since Aug 18, 2026
- 3 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 120 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Antibodies to IL-6 and Use Thereof | 12 in force | to Nov 2030 |
| Agents, Uses and Methods for the Treatment of Synucleinopathy | 11 in force | to Sep 2036 |
| 1- [2- (2,4-Dimethylphenylsulfanyl)-PHENYL] Piperazine as a Compound with Combined Serotonin Reuptake, 5-HT3 and 5-HT1A Activity for the Treatment of Cognitive Impairment | 10 in force | to Jun 2031 |
| Deuterated 1-Piperazino-3-Phenyl-INDANES for Treatment of Schizophrenia | 8 in force | to Jun 2032 |
| 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | 6 in force | to Mar 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,544,685 | Novel 2,3-Dihydroindole Compounds In force · High confidence | In force | High confidence | |
| US 8,022,084 | Polymorphic Forms of a Gabaa Agonist In force · High confidence | In force | High confidence | |
| US 8,969,355 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | In force | High confidence | |
| US 9,095,588 | Process for Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-PHENY]PIPERAZINE or Pharmaceutically Acceptable Salt Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,101,626 | Process For Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine Or Pharmaceutically Acceptable Salt Thereof In force · High confidence | In force | High confidence | |
| US 9,125,908 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | In force | High confidence | |
| US 9,125,909 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · Medium confidence | In force | Medium confidence | |
| US 9,125,910 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · Medium confidence | In force | Medium confidence | |
| US 9,227,946 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment In force · High confidence | In force | High confidence | |
| US 9,744,166 | Therapeutic Uses of Compounds Having Combined SERT, 5-HT3 and 5-HT1A Activity In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 249: 11 patents in force now held by others · 315 patents ended · 35 applications pending · 267 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.